Vincent Angotti - AcelRx Pharmaceuticals CEO, Interim CFO
| ACRXDelisted Stock | USD 1.01 0.01 1.00% |
CEO
Mr. Vincent J. Angotti was appointed as Director and Chief Executive Officer of the Company August 16, 2017. Mr. Angotti comes from XenoPort, Inc. which he joined in 2008 as SVP and chief commercialization officer and was promoted to EVP and COO in 2012 and to CEO in 2015. During his tenure at XenoPort, Mr. Angotti was involved in the reacquisition of Horizant from GSK and implemented a successful rebranding and relaunch strategy leading to XenoPorts acquisition by Arbor Pharmaceuticals, LLC in 2016. Prior to joining XenoPort, Mr. Angotti held senior sales and marketing positions at Reliant Pharmaceuticals, Inc. from 20012008. In his role as senior vice president of sales and marketing at Reliant, Mr. Angotti was integrally involved in the companys MA discussions that concluded with Reliants acquisition by GSK in 2007 since 2017.
| Age | 56 |
| Tenure | 8 years |
| Phone | 650 216 3500 |
| Web | https://www.acelrx.com |
Vincent Angotti Latest Insider Activity
Tracking and analyzing the buying and selling activities of Vincent Angotti against AcelRx Pharmaceuticals stock is an integral part of due diligence when investing in AcelRx Pharmaceuticals. Vincent Angotti insider activity provides valuable insight into whether AcelRx Pharmaceuticals is net buyers or sellers over its current business cycle. Note, AcelRx Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell AcelRx Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Vincent Angotti over a month ago Acquisition by Vincent Angotti of 5000 shares of Talphera at 0.6399 subject to Rule 16b-3 | ||
Vincent Angotti over a month ago Acquisition by Vincent Angotti of 5000 shares of Talphera at 0.7299 subject to Rule 16b-3 | ||
Vincent Angotti over two months ago Disposition of 1623 shares by Vincent Angotti of Talphera at 1.3 subject to Rule 16b-3 | ||
Vincent Angotti over three months ago Acquisition by Vincent Angotti of 7260 shares of Talphera at 1.0466 subject to Rule 16b-3 |
AcelRx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3222) % which means that it has lost $0.3222 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5112) %, meaning that it created substantial loss on money invested by shareholders. AcelRx Pharmaceuticals' management efficiency ratios could be used to measure how well AcelRx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.AcelRx Pharmaceuticals currently holds 10.42 M in liabilities with Debt to Equity (D/E) ratio of 0.43, which is about average as compared to similar companies. AcelRx Pharmaceuticals has a current ratio of 1.77, which is within standard range for the sector. Note, when we think about AcelRx Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 11 records | CEO Age | ||
| Chintu Patel | Amneal Pharmaceuticals, Class | 49 | |
| Brendan OGrady | Assertio Therapeutics | N/A | |
| David RPh | Evoke Pharma | 60 | |
| Chirag Patel | Amneal Pharmaceuticals, Class | 58 | |
| Keith Kendall | Aquestive Therapeutics | 66 | |
| Irwin Simon | Tilray Inc | 67 | |
| Paul Josephs | Lifecore Biomedical | 60 | |
| David Gonyer | Evoke Pharma | 60 | |
| Gary Sr | Organogenesis Holdings | 70 | |
| James Hall | Lifecore Biomedical | 62 | |
| Chintu RPh | Amneal Pharmaceuticals, Class | 53 | |
Management Performance
| Return On Equity | -0.51 | |||
| Return On Asset | -0.32 |
AcelRx Pharmaceuticals Leadership Team
Elected by the shareholders, the AcelRx Pharmaceuticals' board of directors comprises two types of representatives: AcelRx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AcelRx. The board's role is to monitor AcelRx Pharmaceuticals' management team and ensure that shareholders' interests are well served. AcelRx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AcelRx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vincent Angotti, CEO, Interim CFO | ||
| Anil Dasu, Chief Officer | ||
| Lawrence Hamel, Chief Devel. Officer | ||
| Pamela MD, Chief CoFounder | ||
| Raffi Asadorian, Chief Officer |
AcelRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AcelRx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (28.28) % | |||
| Current Valuation | 3.25 M | |||
| Shares Outstanding | 16.95 M | |||
| Shares Owned By Insiders | 2.63 % | |||
| Shares Owned By Institutions | 38.88 % | |||
| Number Of Shares Shorted | 508.11 K | |||
| Price To Earning | 0.39 X | |||
| Price To Book | 0.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in AcelRx Stock
If you are still planning to invest in AcelRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AcelRx Pharmaceuticals' history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |